ReviewFrontiers in immunology2026
Divergent roles of IL-35 and IL-39 in rheumatoid arthritis: restoring cytokine balance within the IL-12 family.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by persistent synovial inflammation, progressive cartilage destruction, and irreversible bone erosion. Although substantial progress has been made in identifying downstream inflammatory mediators, the upstream regulatory architecture governing immune imbalance in RA remains incompletely understood. Members of the interleukin-12 (IL-12) cytokine family are key regulators of T-cell differentiation and inflammatory amplification. Among them, IL-35 and IL-39 represent functionally opposing yet incompletely characterised cytokines with emerging relevance to RA pathogenesis. IL-35, predominantly produced by regulatory T and B cells, exerts immunosuppressive effects by inhibiting T helper 17 (Th17) responses, expanding regulatory lymphocyte populations, and modulating macrophage polarisation. Evidence suggests dysregulation of the IL-35 axis in RA, characterised by reduced systemic levels but relative synovial upregulation, possibly reflecting a compensatory response to persistent inflammation. In contrast, IL-39, derived from activated B cells and myeloid cells, promotes inflammatory cascades through STAT1/STAT3 signalling. Circulating IL-39 levels correlate with disease activity and inflammatory biomarkers, supporting its potential role in sustaining immune activation. This mini-review synthesises current evidence on the divergent immunobiology of IL-35 and IL-39 in RA, evaluates their mechanistic pathways, and discusses their translational implications as biomarkers and therapeutic targets. By examining IL-35 alongside the relatively understudied cytokine IL-39, we highlight the added value of this pairing in clarifying their shared and distinct biological functions. We propose that disruption of regulatory-inflammatory equilibrium within the IL-12 cytokine family provides a conceptual framework for understanding immune dysregulation in RA and may inform precision immunomodulatory strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.